LUPRON DEPOT offers a proprietary delivery system and formulation designed with you and your patient’s experience in mind.
LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1‑month, 22.5 mg for 3-month, 30 mg for 4‑month, and 45 mg for 6‑month administration are indicated for the palliative treatment of advanced prostatic cancer.
US-LUPR-190307
Please see accompanying Full Prescribing Information.
LUPRON DEPOT [package insert]. North Chicago, IL: AbbVie Inc; 2019.
Data on file. AbbVie Inc. ABVRRTI63636.
Nygren O, Olofsson E, Johannson L. NIOSH definition of closed-system drug-transfer devices. Ann Occup Hyg. 2009;53(5):549. doi:10.1093/annhyg/mep030.
Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc; 2019.
Trelstar [package insert]. Madison, NJ: Allergan USA, Inc; 2018.
Zoladex 3.6 mg [package insert]. Lake Forest, IL: TerSera Therapeutics LLC; 2019.
Zoladex 10.8 mg [package insert]. Lake Forest, IL: TerSera Therapeutics LLC; 2019.
Vantas [package insert]. Malvern, PA: Endo Pharmaceuticals Solutions Inc; 2017.
Firmagon [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2016.
Dosing and administration. Trelstar website. http://www.trelstar.com/dosing-and-administration. Accessed October 8, 2019.
Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997;28(1):43-70. doi:10.1016/S0169-409X(97)00050-1.
Data on file. AbbVie Inc. LuproLink clinic count. 2018.